p15 expression differentiates naevus from melanoma
7 December 2016Recent study data support the hypothesis that decreased p15 expression is a robust biomarker for distinguishing naevus from melanoma.
Prolonged survival in stage III melanoma with ipilimumab as adjuvant therapy
6 December 2016As adjuvant therapy for high-risk stage III melanoma, ipilimumab resulted in significantly higher rates of recurrence-free survival, overall survival, and distant metastasis–free survival than placebo, according to trial results published in the New England Journal of Medicine.
Interval cancers after skin cancer screening
6 December 2016Interval melanomas within the German SCREEN project were thinner and had a slightly greater proportion of lentigo maligna melanomas, according to an analysis of data from programme participants. By comparison, nodular melanomas were less frequent.
NZ banning sunbeds will have little impact on jobs
2 December 2016Banning sunbed services in New Zealand would help reduce skin cancer rates and only have a minimal impact on businesses and jobs, new University of Otago research suggests.
No safe exposure limit for UV radiation from sunbeds
30 November 2016There is no safe exposure limit for UV radiation from sunbeds, concludes an independent scientific committee of the European Commission.
Safety profile of nivolumab monotherapy
30 November 2016Treatment-related adverse events with nivolumab monotherapy were primarily low grade, and most resolved with established safety guidelines, according to authors of a study published in the Journal of Clinical Oncology.
p15 expression differentiates naevus from melanoma
28 November 2016Recent study data support the hypothesis that decreased p15 expression is a robust biomarker for distinguishing naevus from melanoma.
Cancer information seeking in NZ: insights for providers
24 November 2016Organisations seeking to establish themselves as leading cancer information sources for the public need to understand patterns and motivators for information seeking, according to authors of a recent study among adult New Zealanders.
PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma
22 November 2016In this study, first-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56%.
Skills training for patients at risk of second primary melanoma
18 November 2016A structured skills training programme for skin self-examination among patients with melanoma and their partners may enhance early detection and relieve some of the burden on health services, according to authors of this study.